These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 20674669)
1. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Curtis JR; Jain A; Askling J; Bridges SL; Carmona L; Dixon W; Finckh A; Hyrich K; Greenberg JD; Kremer J; Listing J; Michaud K; Mikuls T; Shadick N; Solomon DH; Weinblatt ME; Wolfe F; Zink A Semin Arthritis Rheum; 2010 Aug; 40(1):2-14.e1. PubMed ID: 20674669 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823 [TBL] [Abstract][Full Text] [Related]
3. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Michaud K; Berglind N; Franzén S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Nyberg F; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Askling J Ann Rheum Dis; 2016 Oct; 75(10):1797-805. PubMed ID: 26857699 [TBL] [Abstract][Full Text] [Related]
4. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. Vashisht P; Sayles H; Cannella AC; Mikuls TR; Michaud K Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1478-88. PubMed ID: 26866293 [TBL] [Abstract][Full Text] [Related]
5. "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients". Pappas DA; Kremer JM; Reed G; Greenberg JD; Curtis JR BMC Musculoskelet Disord; 2014 Apr; 15():113. PubMed ID: 24690143 [TBL] [Abstract][Full Text] [Related]
6. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL; Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894 [TBL] [Abstract][Full Text] [Related]
8. The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs. Pombo-Suarez M; Gomez-Reino J Pharmacol Res; 2019 Oct; 148():104410. PubMed ID: 31461667 [TBL] [Abstract][Full Text] [Related]
9. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Kievit W; Fransen J; Oerlemans AJ; Kuper HH; van der Laar MA; de Rooij DJ; De Gendt CM; Ronday KH; Jansen TL; van Oijen PC; Brus HL; Adang EM; van Riel PL Ann Rheum Dis; 2007 Nov; 66(11):1473-8. PubMed ID: 17426065 [TBL] [Abstract][Full Text] [Related]
10. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686 [TBL] [Abstract][Full Text] [Related]
11. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Raaschou P; Simard JF; Neovius M; Askling J; Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513 [TBL] [Abstract][Full Text] [Related]
12. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908 [TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589 [TBL] [Abstract][Full Text] [Related]
14. A paradigm shift in studies based on rheumatoid arthritis clinical registries. Cho SK; Sung YK Korean J Intern Med; 2019 Sep; 34(5):974-981. PubMed ID: 30759964 [TBL] [Abstract][Full Text] [Related]
15. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Mercer LK; Askling J; Raaschou P; Dixon WG; Dreyer L; Hetland ML; Strangfeld A; Zink A; Mariette X; Finckh A; Canhao H; Iannone F; Zavada J; Morel J; Gottenberg JE; Hyrich KL; Listing J Ann Rheum Dis; 2017 Feb; 76(2):386-391. PubMed ID: 27307502 [TBL] [Abstract][Full Text] [Related]
16. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Clark W; Jobanputra P; Barton P; Burls A Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461 [TBL] [Abstract][Full Text] [Related]
17. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries. Nasir A; Greenberg JD Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666 [TBL] [Abstract][Full Text] [Related]
18. Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. Verstappen SM; Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Holmqvist M; Horne L; Lampl K; Michaud K; Nyberg F; Pappas DA; Reed G; Symmons DP; Tanaka E; Tran TN; Yamanaka H; Ho M Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1637-45. PubMed ID: 26201948 [TBL] [Abstract][Full Text] [Related]
19. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Nyberg F; Askling J; Berglind N; Franzén S; Ho M; Holmqvist M; Horne L; Lampl K; Michaud K; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Greenberg JD Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1121-32. PubMed ID: 26303866 [TBL] [Abstract][Full Text] [Related]
20. Design characteristics of the Corrona Japan rheumatoid arthritis registry. Yamanaka H; Kishimoto M; Pappas DA; Greenberg JD; Kremer JM; Tanaka Y Mod Rheumatol; 2018 Jan; 28(1):95-100. PubMed ID: 28448195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]